KLK3 and prostate carcinoma: There has been a wide range of evidence published on the effectiveness of systematic prostate-specific-antigen–based screening in reducing prostate-cancer mortality [1–4]; however, associated estimates of costs and cost-effectiveness from real-world data have received much less attention [5, 6].